[Corneal subepithelial infiltrates that developed following intravitreous injection of bevacizumab].
BACKGROUND
Anti-vascular endothelial growth factor (anti-VEGF) therapies including intravitrous bevacizumab injection (IVB) emerged as an effective treatment for various fundus diseases. Reports of adverse reactions derived from bevacizumab itself are rare. We report a case in which corneal subepithelial infiltrates developed following IVB.


METHODS
A sixty-six-year-old man presented with visual acuity loss due to cystic macular edema secondary to branch retinal vein occlusion. He developed vascular congestion and subepithelial infiltrates in the peripheral cornea on day 2 following the first IVB. The findings resolved with topical steroid in twelve days.


CONCLUSIONS
A case of subepithelial infiltrate in the peripheral cornea following IVB is reported. Since infiltrates were located along, and associated with the congestion of, the limbal vascular arcade, an innate immune response to bevacizumab may be indicated.
Department of Ophthalmology, Saitama Medical University, 38 Morohongo, Moroyama, Iruma-gun, Saitama-ken 350-0495, Japan. YFA47868@nifty.com
Fumi
F
Yamato
Daisuke
D
Imai
Keisuke
K
Mori
Shin
S
Yoneya
D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D003316:Corneal Diseases / Q000139:chemically induced*; D006801:Humans; D007267:Injections; D008297:Male; D012170:Retinal Vein Occlusion / Q000175:diagnosis / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology*; D014792:Visual Acuity / Q000187:drug effects*
D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab